The UK's Asthma Research Landscape
The United Kingdom has long punched above its weight in respiratory research. Institutions like the NIHR Imperial Biomedical Research Centre in London and the respiratory teams at Southampton General Hospital run some of the most advanced asthma studies globally. The country also maintains the UK Severe Asthma Registry, a comprehensive database that tracks how patients respond to different treatments over time, helping researchers spot patterns and refine care.
A major development arrived in late 2025, when the Medicines and Healthcare products Regulatory Agency (MHRA) authorised Exdensur (depemokimab)—the first ultra-long-acting biologic for asthma with type 2 inflammation. Unlike earlier biologics that require injections every two to four weeks, depemokimab is dosed just twice a year. The approval was based on the SWIFT and ANCHOR phase III trials, which showed sustained reductions in exacerbations and fewer hospitalisations. While this particular drug has now received marketing authorisation, many other investigational treatments remain in the trial pipeline, and UK research centres are actively recruiting participants.
The biologics landscape in the UK is already quite mature. Treatments like mepolizumab (Nucala), benralizumab (Fasenra), omalizumab (Xolair), dupilumab (Dupixent), and tezepelumab (Tezspire) are commissioned by the NHS for eligible patients with severe asthma. Each targets a different inflammatory pathway, and clinical trials continue to explore new candidates, combination approaches, and longer-acting formulations.
What Kinds of Trials Are Running Right Now
Asthma clinical trials in the UK fall into several broad categories, and understanding which one might suit you starts with knowing what is out there.
Biologic therapy trials tend to attract the most attention. These studies test monoclonal antibodies designed to block specific inflammatory signals involved in asthma. They usually recruit patients whose asthma has an eosinophilic or allergic component and who remain symptomatic despite high-dose inhaled corticosteroids. Some trials compare a new biologic against an existing one, while others test whether a biologic can be given less frequently or at a lower dose without losing effectiveness.
A recent analysis published in ERJ Open Research looked at data from the UK Severe Asthma Registry and found that biologics can be effective even in patients who would not have met the strict eligibility criteria of the original phase III trials. This matters because it suggests that real-world prescribing may safely extend to a broader group than the research initially covered.
Self-management and digital health trials are another active area. The IMP2ART study, a cluster randomised controlled trial run across UK primary care practices, is testing whether a structured approach to supported self-management can improve asthma control. Researchers are also validating remote lung-function monitoring tools, which could make it easier for patients to participate in studies without travelling to a hospital every few weeks.
Precision medicine and diagnostic trials focus on identifying which patients will respond to which treatments before they even start. This includes studies on biomarkers, genetic profiling, and new ways to measure airway inflammation at home.
Here is a snapshot of the main trial types you might encounter:
| Trial Category | Typical Focus | Who It Suits | Visit Frequency | Main Advantage | Things to Consider |
|---|
| Biologic trials | New monoclonal antibodies | Severe eosinophilic or allergic asthma | Every 4-12 weeks | Access to advanced treatments not yet on NHS | Regular blood tests and monitoring |
| Self-management trials | Behavioural and digital interventions | Mild to moderate asthma | Variable, often remote | Improves day-to-day control | Requires active engagement with apps or diaries |
| Diagnostic trials | Biomarkers, remote monitoring | Any asthma severity | Short-term, sometimes home-based | Convenience, contributes to better diagnostics | May involve unfamiliar technology |
| Inhaled therapy trials | New inhalers or combinations | Mild to severe asthma | Every 4-8 weeks | Often simpler than biologic trials | May require washout of current medications |
A Patient's Perspective
Carly Sylvester, a woman from Jersey, first experienced an asthma attack at age seven while sleeping on a feather pillow at a friend's house. She describes the memory vividly: struggling to breathe in a hospital corridor, terrified. Her symptoms worsened through her twenties, and despite trying inhalers, tablets, nebulisers, and steroids, nothing brought lasting relief.
In her late twenties, specialists at Southampton General Hospital offered her biologic therapy with mepolizumab. She now administers a monthly injection at home and visits Southampton twice a year for check-ups. The transformation was dramatic enough that she completed the London Marathon—something she could not have imagined during her worst years. Speaking about the new Medical Innovation Institute being established at Southampton, she called it "very, very exciting" and said it would "change many people's lives."
Stories like Carly's are not unusual among patients who enter clinical trials or receive biologic treatment through the NHS. The key is getting connected to the right research team, which often starts with a conversation at your local GP surgery or asthma clinic.
How to Find and Join a Trial
The process of joining a clinical trial in the UK is more straightforward than many people assume, though it does require patience and persistence.
Your first stop should be the NIHR Be Part of Research website. This is a searchable database of studies actively recruiting across England, Scotland, Wales, and Northern Ireland. You can filter by condition, location, and trial type. Asthma + Lung UK also maintains information about ongoing respiratory research and can point you toward relevant studies.
A GP or respiratory consultant referral is often the most direct route. Specialists at NHS severe asthma centres—there are dedicated clinics in London, Manchester, Birmingham, Edinburgh, Glasgow, Cardiff, and Belfast—regularly screen patients for trial eligibility. If you are already under the care of a respiratory team, ask at your next appointment whether any studies might be suitable.
Eligibility criteria vary by trial, but common requirements include a confirmed asthma diagnosis, a certain level of symptom severity or exacerbation history, and specific blood or sputum markers (such as eosinophil counts). Some trials require participants to be on stable doses of current medications for a set period before enrolment. Others may ask you to stop certain treatments temporarily, which is something to discuss carefully with the research team.
One important point: there is no cost to participate in NHS-affiliated clinical trials. The study sponsor covers all trial-related medications, tests, and monitoring. Travel expenses to and from the trial site are usually reimbursed. You do not need private health insurance to take part.
What Happens Once You Enrol
After an initial screening visit confirms your eligibility, you will typically go through a baseline assessment that includes lung function tests, blood work, and quality-of-life questionnaires. The research team will explain the trial schedule, what each visit involves, and how to contact them if you have concerns between appointments.
Some trials are randomised and placebo-controlled, meaning you may receive the active treatment or a placebo, and neither you nor the research team will know which one you are on. Others are open-label, where everyone receives the investigational treatment. The consent form will spell out exactly what to expect, and you can withdraw at any time without affecting your usual NHS care.
The commitment can range from a few weeks to a couple of years, depending on the study. Biologic trials often run for 12 to 52 weeks, with an option to continue into an extension phase if the treatment proves beneficial.
Taking the Next Step
If you have been struggling with asthma that disrupts your sleep, limits your exercise, or lands you in hospital more often than you would like, a clinical trial might open a door that standard care has not. The UK's research infrastructure—from the NIHR clinical research network to specialist centres scattered across the country—means there is likely a study not too far from where you live.
Start by visiting the NIHR Be Part of Research site or speaking with your asthma nurse. Ask whether your local hospital has a respiratory research team. The question worth asking is not just "what can I try next?" but "what is being tested right now that could make a difference?"
The patients who benefit most from clinical trials are often the ones who take the initiative to ask.
研究の知恵